

Recombinant Influenza B virus NA Protein, His-tagged

Cat. No. NA-03I **Lot. No.** (See product label)

SPECIFICATION

Product Overview	This Influenza virus neuraminidase protein is derived from the NA sequence of the Influenza B/Austria/1359417/2021 NA, expressing aa 35-466, and fused with a polyhistidine tag at the C-terminus. The influenza virus neuraminidase protein is expressed in HEK293 cells. This virus is recommended by WHO for inclusion in the quadrivalent and trivalent vaccines for use in the 2022 southern hemisphere influenza season. (Accession: GISAID EPI1868374)
Species	Influenza B virus (B/Austria/1359417/2021)
Source	HEK293
ProteinLength	35-466 a.a.
Description	Influenza B virus is the only species in the genus Betainfluenzavirus in the virus family Orthomyxoviridae. Influenza B virus is only known to infect humans and seals and this is believed to account for the lack of associated influenza pandemics in contrast with those caused by the morphologically similar influenza A virus, although both mutate by both antigenic drift and reassortment. However, it is thought that Influenza B virus could cause significant morbidity and mortality worldwide, particularly in adolescents and schoolchildren. WHO convenes technical consultations in February and September each year to recommend viruses for inclusion in influenza vaccines for the northern and southern hemisphere influenza seasons, respectively. Flu vaccines are based on predicting which mutants of H1N1, H3N2, H1N2, and influenza B will proliferate in the next season. Separate vaccines

 Tel: 1-631-559-9269 1-516-512-3133

 Email: info@creative-biomart.com  Fax: 1-631-938-8127

 45-1 Ramsey Road, Shirley, NY 11967, USA

are developed for the Northern and Southern Hemispheres in preparation for their annual epidemics. One influenza A (H1N1), one influenza A (H3N2), and one or two influenza B viruses (depending on the vaccine) are included in each season's influenza vaccines (CDC, 2019). WHO has identified four strains as the most likely to circulate in the 2020-2021 influenza season, including Influenza B [B/Washington/02/2019] virus.

Form	Liquid
Molecular Mass	Expected Molecular Weight: 49 kDa Observed Molecular Weight: 60 kDa
Purity	> 95 %
Storage	Short Term Storage: -80 centigrade Long Term Storage: -80 centigrade Can be frozen, but avoid multiple freeze-thaw cycles.
Concentration	2.97 mg/mL
Storage Buffer	DPBS
Shipping	Dry ice
SDS-PAGE	Coomassie-stained SDS-PAGE showing purified Influenza neuraminidase protein.